LIFE: Update on Sensor longevity

Reference is made to Lifecare AS (LIFE) stock exchange notification 6 February2023.

Today, Lifecare is pleased to announce that a sensor first used in our ongoingClinical Development Study has confirmed an operational longevity of 12 weeks ina continued laboratory (in vitro) set up. This is yet another importantmilestone in the development of our Sencell technology for Continuous GlucoseMonitoring (CGM).

The achievement was made possible through the use of a sensor that was firstimplanted and tested clinically in human (in vivo), and then explanted andtransferred to continued testing in vitro. The operational longevity in thiscombined in vivo and in vitro experiment has passed 12 weeks and is stillongoing.

This innovative approach allowed Lifecare to demonstrate the longevity of theSencell sensor in a more realistic and relevant environment, as well as todocument an impressive sensor robustness. The experiment also confirms thestability of the chemistry used in the in the sensor and demonstrates that thetechnology has a superior longevity compared to existing needle-based CGMsensors.

The 12-week longevity achievement is an important confirmation towardsLifecare's main goal of achieving a longevity of 6 months or more in vivo forits Sencell sensor. It confirms the potential of the technology to providelong-term and accurate glucose monitoring for people with diabetes, whilereducing the need for frequent sensor replacements.

-We are satisfied to tick-off yet another achievement confirming that we are ontrack with our development to provide a long-term and accurate ContinuousGlucose Monitor for people with diabetes, Lifecare strive to ensure high qualityin all stages of our development, and this ongoing experiment forms an importantand reassuring base for our upcoming clinical longevity study, says JoacimHolter, CEO of Lifecare.


Lifecare AS is a clinical stage medical sensor company developing technology forsensing and monitoring of various body analytes. Lifecare's main focus is tobring the next generation of Continuous Glucose Monitoring ("CGM") systems tomarket. Lifecare enables osmotic pressure as sensing principle, combined withthe ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") onthe sensor body for read-out of pressure variations. LifecareŽs sensortechnology is referred to as "Sencell" and is suitable for identifying andmonitoring the occurrence of a wide range of analytes and molecules in the humanbody.


For further information, please contact: Joacim Holter, CEO, Lifecare AS,, +47 40 05 90 40

This information is considered to be inside information pursuant to the EUMarket Abuse Regulation and is subject to the disclosure requirements pursuantto Section 5-12 the Norwegian Securities Trading Act. This stock exchangeannouncement was published by Joacim Holter, CEO at Lifecare AS, on 11 April2023 at 8:15 AM CET.